• PDF / 169,909 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 86 Downloads / 238 Views

DOWNLOAD

REPORT

503/20/0861-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 5 Sep 2020 No. 861

1

Recommend Documents

Adalimumab in Psoriatic Arthritis

152 78 48KB

Depression care for US prostate cancer patients: more QALYs, lower cost

140 79 163KB

Trends in psoriatic arthritis epidemiology in Poland

152 111 602KB

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year

143 49 2MB

Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis

181 17 150KB

Clinical Presentation of Sine Syndrome in Psoriatic Arthritis

174 13 2MB

Canagliflozin in T2DM-related nephropathy improves QALYs, reduces cost

181 44 164KB

Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis

178 95 917KB

Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Ana

148 28 743KB

Carpal tunnel syndrome in patients with rheumatoid arthritis and psoriatic arthritis: an electrophysiological and ultras

177 95 540KB

Psoriatic Arthritis and Psoriasis Pathology and Clinical Aspects

166 61 10MB

Ixekizumab

133 70 10MB